Calcitonin Gene-related Peptide Receptor Antagonist [EPC] — Patent Landscape

Aggregated US Orange Book patent estate across every drug in the calcitonin gene-related peptide receptor antagonist [epc] class. 48 active patents protecting 3 drugs. First major cliff: 2031. Daily refresh.

3
Drugs in class
48
Active US patents
63/100
Avg vulnerability
$865M
Annual revenue covered

Originators

AbbVie 47 patents Pfizer 1 patents

Cliff calendar — next 15 years

8
31
5
32
5
33
17
35
3
39

Drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Ubrelvy
UBROGEPANT
 AbbVie 27 56 $664M 2031-11-10
Qulipta
ATOGEPANT
 AbbVie 20 56 $201M 2031-11-10
Zavzpret
Zavegepant Hydrochloride
 Pfizer 1 76 — 2031-10-07

Most attackable patents

Patent Drug Type Vuln Expiry
8481546 Zavzpret method of use 76 2031-10-07
12383545 Qulipta method of use 75 2039-06-06
12383545 Qulipta method of use 75 2039-06-06
12383545 Qulipta method of use 75 2039-06-06
12090148 Qulipta method of use 75 2041-07-29
12090148 Qulipta method of use 75 2041-07-29
12090148 Qulipta method of use 75 2041-07-29
12329750 Ubrelvy method of use 75 2041-12-22
12070450 Ubrelvy method of use 75 2041-12-22
11857542 Ubrelvy method of use 75 2041-12-22

Strongest defences

Patent Drug Type Vuln Expiry
8912210 Ubrelvy composition of matter 4 2033-12-23
8912210 Ubrelvy composition of matter 4 2033-12-23
9850246 Qulipta composition of matter 4 2033-03-13
9850246 Qulipta composition of matter 4 2033-03-13
9850246 Qulipta composition of matter 4 2033-03-13
10117836 Ubrelvy formulation 42 2035-01-30
10117836 Ubrelvy formulation 42 2035-01-30
10117836 Qulipta formulation 42 2035-01-30
10117836 Qulipta formulation 42 2035-01-30
10117836 Qulipta formulation 42 2035-01-30

Related